Success Metrics

Clinical Success Rate
90.0%

Based on 27 completed trials

Completion Rate
90%(27/30)
Active Trials
1(3%)
Results Posted
15%(4 trials)
Terminated
3(8%)

Phase Distribution

Ph phase_1
3
8%
Ph phase_2
9
24%
Ph phase_4
3
8%
Ph not_applicable
10
27%
Ph phase_3
10
27%

Phase Distribution

3

Early Stage

9

Mid Stage

13

Late Stage

Phase Distribution35 total trials
Phase 1Safety & dosage
3(8.6%)
Phase 2Efficacy & side effects
9(25.7%)
Phase 3Large-scale testing
10(28.6%)
Phase 4Post-market surveillance
3(8.6%)
N/ANon-phased studies
10(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.1%

27 of 31 finished

Non-Completion Rate

12.9%

4 ended early

Currently Active

1

trials recruiting

Total Trials

37

all time

Status Distribution
Active(3)
Completed(27)
Terminated(4)
Other(3)

Detailed Status

Completed27
Terminated3
unknown3
Not yet recruiting2
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
37
Active
1
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (8.6%)
Phase 29 (25.7%)
Phase 310 (28.6%)
Phase 43 (8.6%)
N/A10 (28.6%)

Trials by Status

withdrawn13%
terminated38%
active_not_recruiting13%
completed2773%
unknown38%
not_yet_recruiting25%

Recent Activity

Clinical Trials (37)

Showing 20 of 37 trialsScroll for more
NCT07559032Not Applicable

Amphotericin B for Breakthrough Fungal Infections After Triazole Prophylaxis in Hematological Patients

Not Yet Recruiting
NCT07191756

Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study

Active Not Recruiting
NCT06926569Not Applicable

Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis

Not Yet Recruiting
NCT02629419Phase 2

CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis

Completed
NCT06413056Phase 4

Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection

Completed
NCT04031833Phase 1

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)

Completed
NCT05541107Phase 3

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3

Unknown
NCT00885703Phase 1

High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals

Completed
NCT00000639Not Applicable

A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis

Completed
NCT00001065Phase 2

A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole

Completed
NCT00000776Phase 2

Dexamethasone in Cryptococcal Meningitis

Completed
NCT03112031Phase 2

Treatment With Tamoxifen in Cryptococcal Meningitis

Completed
NCT04140461Phase 3

AmB Dose for Cryptococcal Meningitis

Unknown
NCT04018417Phase 2

Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections.

Withdrawn
NCT01615809Phase 2

Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia

Completed
NCT00216346Phase 3

Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis

Completed
NCT00491426

Antimicrobial PK in Infants With Suspected or Confirmed Infection

Completed
NCT00145249Phase 2

Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis

Completed
NCT00000708Not Applicable

Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

Completed
NCT00001017Phase 3

Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS

Completed

Drug Details

Intervention Type
DRUG
Total Trials
37